Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RESTORE extension study of Lucentis for diabetic macular edema
NL-OMON33189Phase 3Not yet recruiting
- Sponsor
- Novartis
- Start
- Sep 2009
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of ranibizumab in diabetic macular edema (DME), sponsored by Novartis. Primary endpoint: Incidence and severity of treatment-emergent adverse events over 24 months. Planned start Sep 2009; status: not yet recruiting.
02
Drugs
ranibizumab
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on NL-OMON33189.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON33189.